Latest news with #BCRX
Yahoo
06-05-2025
- Business
- Yahoo
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BioCryst Pharmaceuticals (BCRX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on May 5, 2025, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This drugmaker is expected to post quarterly loss of $0.07 per share in its upcoming report, which represents a year-over-year change of +58.8%. Revenues are expected to be $126.59 million, up 36.5% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 3.13% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Yahoo
06-05-2025
- Business
- Yahoo
Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday
We recently published a list of Why These 10 Firms Soared on Monday. In this article, we are going to take a look at where BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stands against other Monday's best performers. The stock market kicked off the trading week on a negative note as investors sold off on a new round of uncertainties from President Donald Trump's tariff policies. The Nasdaq fell by 0.74 percent, while the S&P 500 dropped 0.64 percent and the Dow Jones was down by 0.24 percent. Over the weekend, Trump told reporters that the US was negotiating with many countries, 'but at the end of this, I'll set my own deals — because I set the deal, they don't set the deal.' He added that he had no intentions to talk with Chinese President Xi Jinping, dampening hopes of a potential negotiation between the two of the world's largest economies. Beyond the major indices, 10 companies stood out with strong gains amid a flurry of fresh developments. In this article, we name Monday's 10 best performers and detail the reasons behind their gains. To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume. Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday A scientist in a lab coat observing a line of medicine pills in a container. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) BioCryst Pharmaceuticals jumped by 23.52 percent on Monday, a second straight day, ending the day at $11.03 apiece following its impressive earnings performance in the first quarter, coupled with a highly optimistic outlook for the rest of the year. In a statement, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it swung to a net income of $32,000 from a net loss of $35.38 million in the same period a year earlier as revenues jumped by 57 percent to $145.5 million from $92.76 million year-on-year, thanks to the strong performance of its hereditary angioedema treatment, Orladeyo. Looking ahead, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) said it now expects to be fully profitable for the rest of the year ahead of its original target. Revenues from Orladeyo alone were expected to settle between $580 million and $600 million, higher than the $535 million to $550 million targeted previously. Full-year operating expenses were also targeted to settle only between $440 million and $450 million, from the previous $425 million to $435 million. Overall, BCRX ranks 2nd on our list of Monday's best performers. While we acknowledge the potential of BCRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than BCRX but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
Yahoo
10-02-2025
- Business
- Yahoo
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2024 financial results on Monday, February 24, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live webcast and replay of the call will be available online in the investors section of the company website at About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit or follow us on LinkedIn. BCRXW Contact:John Bluth+1 919 859 7910jbluth@
